The Effect of Vitamin D Administration on Blood Levels Malondialdehyde (MDA) Blood in Male White Mice (Rattus Norvegicus) With Chronic Kidney Failure (CKF)
Main Article Content
Abstract
Chronic renal failure is a progressive and irreversible structural or functional disorder of the kidneys that causes a decline in kidney function. Oxidative stress in CKD occurs due to decreased expression of 25-hydroxyvitamin D-1α-hydroxylase (1αOHase) which causes impaired regulation of calcitriol or the active metabolite of renal vitamin D. Malondialdehyde (MDA) is the end product of polyunsaturated lipid peroxidation or can be called polyunsaturated fatty acids that occur due to increased oxidative stress in the body. Based on this, researchers are interested in examining the effect of vitamin D administration on blood MDA levels in chronic renal failure conducted in male rats. This study was an experimental study with a post-test only control group design. The subjects were male Wistar rats, 2 months old, weighing 150-300 grams, with inclusion criteria. Exclusion criteria included rats with physical disabilities and visibly ill. This study used 24 white mice. Data were analyzed using one-way ANOVA mean difference test and Tukey's post hoc test to determine differences between test groups according to the measurement time, which showed significant differences in mean body weight, mean blood pressure, and MDA levels with a p value <0.05. Vitamin D administration can reduce MDA levels in male rats (Rattus norvegicus) with CKD.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
References
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E. and Hsu, C. (2004) ‘Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization’, New England Journal of Medicine, 351(13), pp. 1296–1305. doi: 10.1056/nejmoa041031.
Rattazzi, M., Bertacco, E., Del Vecchio, A., Puato, M., Faggin, E. and Pauletto, P. (2013) ‘Aortic valve calcification in chronic kidney disease’, Nephrology Dialysis Transplantation, 28(12), pp. 2968–2976. doi: 10.1093/ndt/gft310.
Xu, G., Luo, K., Liu, H., Huang, T., Fang, X. and Tu, W. (2015) ‘The progress of inflammation and oxidative stress in patients with chronic kidney disease’, Renal Failure, 37(1), pp. 45–49. doi: 10.3109/0886022X.2014.964141.
Xu, S., Chen, Y. H., Tan, Z. X., Xie, D. D., Zhang, C., Xia, M. Z., Wang, H., Zhao, H., Xu, D. X. and Yu, D. X. (2015) ‘Vitamin D pretreatment alleviates renal oxidative stress in lipopolysaccharide-induced acute kidney injury’, Journal of Steroid Biochemistry and Molecular Biology, 152, pp. 133–141. doi: 10.1016/j.jsbmb.2015.05.009.
Šimoliūnas, E., Rinkūnaitė, I., Bukelskienė, Ž. and Bukelskienė, V. (2019) ‘Bioavailability of different vitamin D oral supplements in laboratory animal model’, Medicina (Lithuania), 55(6), pp. 1–7. doi: 10.3390/medicina55060265.
Tucker, P. S., Dalbo, V. J., Han, T., & Kingsley, M. I. (2013). Clinical and research markers of oxidative stress in chronic kidney disease. Biomarkers, 18(2), 103–115. https://doi.org/10.3109/1354750X.2012.749302
Singh, Z., Karthigesu, I. P., Singh, P. and Kaur, R. (2014) ‘Use of malondialdehyde as a biomarker for assessing oxidative stress in different disease pathologies: A review’, Iranian Journal of Public Health, 43(3), pp. 7–16.
Sagar, P., Pranay, K., Shekhar, R., Singh, P. P., & Kumar, P. (2023). Serum malondialdehyde in different stages of chronic renal disorader. Asian Journal of Medical Sciences, 14(6), 113–118.
Montesa, P. M. J., Gonzalez Rico, M. A., Solis Salguero, M. A., Torregrosa Maicas, I., Tormos Munoz, M. C., Saez Tormo, G., Juan Garcia, I., & Miguel Carrasco, A. (2009). [Study of oxidative stress in advanced kidney disease]. Nefrologia, 29(5), 463–473. https://doi.org/DOI: 10.3265/Nefrologia.2009.29.5.5493.en.full
Tomás-Simó, P., D’Marco, L., Romero-Parra, M., Tormos-Munoz, M. C., Saez, G., Torregrosa, I., Estan-Capell, N., Miguel, A., Gorriz, J. L., & Purchades, M. J. (2021). Oxidative Stress in Non-Dialysis-Dependent Chronic Kidney Disease Patients. International Journal of Environmental Research and Public Health, 18. https://doi.org/10.3390/ijerph2004010001
Pfotenhauer, K. M. and Shubrook, J. H. (2017) ‘Vitamin D deficiency, its role in health and disease, and current supplementation recommendations’, Journal of the American Osteopathic Association, 117(5), pp. 301–305. doi: 10.7556/jaoa.2017.055.
Chen, Y., Liu, W., Sun, T., Huang, Y., Wang, Y., Deb, D. K., Yoon, D., Kong, J., Thadhani, R. and Li, Y. C. (2013) ‘1,25-Dihydroxyvitamin D Promotes Negative Feedback Regulation of TLR Signaling via Targeting MicroRNA-155–SOCS1 in Macrophages’, The Journal of Immunology, 190(7), pp. 3687–3695. doi: 10.4049/jimmunol.1203273.
Yin, K. and Agrawal, D. K. (2014) ‘Vitamin D and inflammatory diseases’, Journal of Inflammation Research, 7(1), pp. 69–87. doi: 10.2147/JIR.S63898.
Jean, G., Souberbielle, J., & Chazot, C. (2017). Vitamin D in Chronic Kidney Disease and Dialysis Patients. Nutrients, 9(4), 328. https://doi.org/10.3390/nu9040328
Zhang, H., Teng, J., Li, Y., He, Y., & He, X. (2014). Vitamin D status and its association with adiposity and oxidative stress in schoolchildren. Nutrition, 30(9), 1040–1044. https://doi.org/doi: 10.1016/j.nut.2014.02.024
Codoñer-Franch P, Tavárez-Alonso S, Simó-Jordá R, Laporta-Martín P, Carratalá-Calvo A, Alonso-Iglesias E. (2012). Vitamin D status is linked to biomarkers of oxidative stress, inflammation, and endothelial activation in obese children. J Pediatr. 2012 Nov;161(5):848-54. doi: 10.1016/j.jpeds.2012.04.046. Epub 2012 Jun 5. PMID: 22677566.
Kandula, P., Dobre, M., Schold, J. D., Schreiber, M. J., Mehrotra, R., & Navaneethan, S. D. (2011). Vitamin D Supplementation in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Observational Studies and Randomized Controlled Trials. Clinical Journal of the American Society of Nephrology, 6(1), 50–62. https://doi.org/10.2215/CJN.03940510
Cupisti, A., Egidi, M. F., Vigo, V., Baronti, M. E., D’Alessandro, C., & Ghiadoni, L. (2015). Vitamin D status and cholecalciferol supplementation in chronic kidney disease patients: An Italian cohort report. International Journal of Nephrology and Renovascular Disease, 151. https://doi.org/10.2147/IJNRD.S90968
Alvarez, J. A., Law, J., Coakley, K. E., Zughaier, S. M., Hao, L., Shahid Salles, K., Wasse, H., Gutiérrez, O. M., Ziegler, T. R. and Tangpricha, V. (2012) ‘High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial.’, The American journal of clinical nutrition, 96(3), pp. 672–679. doi: 10.3945/ajcn.112.040642.
Aytaç, M. B., Deveci, M., Bek, K., Kayabey, Ö., & Ekinci, Z. (2016). Effect of cholecalciferol on local arterial stiffness and endothelial dysfunction in children with chronic kidney disease. Pediatric Nephrology, 31(2), 267–277. https://doi.org/10.1007/s00467-015-3220-5
Meireles, M. S., Kamimura, M. A., Dalboni, M. A., Giffoni De Carvalho, J. T., Aoike, D. T., & Cuppari, L. (2016). Effect of cholecalciferol on vitamin D-regulatory proteins in monocytes and on inflammatory markers in dialysis patients: A randomized controlled trial. Clinical Nutrition, 35(6), 1251–1258. https://doi.org/10.1016/j.clnu.2016.04.014
Amani, R., Abbasnezhad, A., Hajiani, E., Cheraghian, B., Abdoli, Z. and Choghakhori, R. (2018) ‘Vitamin D induced decrease in il-17 and malondialdehyde, and increase in il-10 and total antioxidant capacity levels in patients with irritable bowel syndrome’, Iranian Journal of Immunology, 15(3), pp. 186–196. doi: 10.22034/IJI.2018.39388.
Tang, L., Fang, W., Lin, J., Li, J., Wu, W., & Xu, J. (2018). Vitamin D protects human melanocytes against oxidative damage by activation of Wnt/β-catenin signaling. Laboratory Investigation, 98(12), 1527–1537. https://doi.org/10.1038/s41374-018-0126-4